Search

Background\ud The COVID-19 pandemic has profoundly affected cancer services. Our objective was to determine the effect of the COVID-19 pandemic on decision making and the resulting outcomes for patients with newly diagnosed or recurrent intracranial tumors.\ud \ud Methods\ud We performed a multicenter prospective study of all adult patients discussed in weekly neuro-oncology and skull base multidisciplinary team meetings who had a newly diagnosed or recurrent intracranial (excluding pituitary) tumor between 01 April and 31 May 2020. All patients had at least 30-day follow-up data. Descriptive statistical reporting was used.\ud \ud Results\ud There were 1357 referrals for newly diagnosed or recurrent intracranial tumors across 15 neuro-oncology centers. Of centers with all intracranial tumors, a change in initial management was reported in 8.6% of cases (n = 104/1210). Decisions to change the management plan reduced over time from a peak of 19% referrals at the start of the study to 0% by the end of the study period. Changes in management were reported in 16% (n = 75/466) of cases previously recommended for surgery and 28% of cases previously recommended for chemotherapy (n = 20/72). The reported SARS-CoV-2 infection rate was similar in surgical and non-surgical patients (2.6% vs. 2.4%, P > .9).\ud \ud Conclusions\ud Disruption to neuro-oncology services in the UK caused by the COVID-19 pandemic was most marked in the first month, affecting all diagnoses. Patients considered for chemotherapy were most affected. In those recommended surgical treatment this was successfully completed. Longer-term outcome data will evaluate oncological treatments received by these patients and overall survival.

There are many uncertainties regarding Cystic Fibrosis (CF) treatment. Recently, the first James Lind Alliance (JLA) Priority Setting Partnership (PSP) in CF was completed, bringing clinicians, patients and carers together to identify the Top 10 research priorities. Here we investigate how well the current clinical trials landscape reflects these priorities. Trials in CF were identified through searches of research databases (Pubmed, ANZCTR, EU clinical trials register, ClinicalTrials.gov and ISRCTN). Trials meeting inclusion criteria of registered intervention studies in CF published between 01.012016 and 11.09.2017 were matched to the Top 10 priorities. We identified 259 trials, with 193 fulfilling the inclusion criteria. Only 63 (33%) of these matched one or more of the JLA priorities showing that current clinical trials poorly reflect the JLA Top 10. By increasing awareness of the Top 10 priorities, it is hoped that this will fuel future research in areas important to the CF community.

We present the first forcing interpretation of the future anthropogenic aerosol scenarios of CMIP6 with the simple plumes parameterisation MACv2-SP. The nine scenarios for 2015 to 2100 are based on anthropogenic aerosol emissions for use in CMIP6 (Riahi et al., 2017; Gidden et al., 2018). We use the emissions to scale the observationally informed anthropogenic aerosol optical properties and the associated effect on the cloud albedo of present-day (Fiedler et al., 2017; Stevens et al., 2017) into the future. The resulting scenarios in MACv2-SP are then ranked according to their strength in forcing magnitude and spatial asymmetries for anthropogenic aerosol. All scenarios, except SSP3-70 and SSP4-60, show a decrease in anthropogenic aerosol by 2100 with a range from 108 % to 36 % of the anthropogenic aerosol optical depth in 2015. We estimate the radiative forcing of anthropogenic aerosol from high- and low-end scenarios in the mid-2090s by performing ensembles of simulations with the atmosphere-only configuration of MPI-ESM1.2. MACv2-SP translates the CMIP6 emission scenarios for inducing anthropogenic aerosol forcing. With the implementation in our model, we obtain forcing estimates for both the shortwave instantaneous radiative forcing (RF) and the effective radiative forcing (ERF) of anthropogenic aerosol relative to 1850. Here, ERF accounts for rapid atmospheric adjustments and natural variability internal to the model. The ERF of anthropogenic aerosol for the mid-2090s ranges from −0.15 W m−2 for SSP1-19 to −0.54 W m−2 for SSP3-70, i.e. the mid-2090s ERF is 30 %–108 % of the value in the mid-2000s due to differences in the emission pathway alone. Assuming a stronger Twomey effect changes these ERFs to −0.39 and −0.92 W m−2, respectively, which are similar to estimates obtained from models with complex aerosol parameterisations. The year-to-year standard deviations around 0.3 W m−2 associated with natural variability highlight the necessity to average over sufficiently long time periods for estimating ERF; this is in contrast to RF that is typically well constrained after simulating just 1 year. The scenario interpretation of MACv2-SP will be used within the framework of CMIP6 and other cutting-edge scientific endeavours.